NEJM:小儿肌阵挛性癫痫的肠细胞激酶变异

2018-03-15 zhangfan MedSci原创

研究认为肠细胞激酶杂合突变与小儿肌阵挛性癫痫相关

对于小儿肌阵挛性癫痫认识研究目前仅局限于弥漫性多棘惊厥脑电图(EEG)和微小的显微脑发育不良。

近日研究人员利用Sanger测序法小儿肌阵挛性癫痫患者进行了基因测序,同时研究人员筛选了310名患者,对其进行了DNA熔融曲线分析,并对编码肠细胞激酶(ICK)的基因进行了靶向实时DNA测序。通过概率贝叶斯对数(LOD)分数考察等位基因突变频率,在体外对变体对有丝分裂、凋亡和桡神经母细胞迁移功能进行了测试,并对ICK缺陷小鼠进行了视频脑电图研究。

研究发现K305T (c.914A→C)突变与脑电图确诊的小儿肌阵挛性癫痫相关,310名患者中证实了22名患者存在21中致病性突变(7%),其中K220E, K305T, A615T和 R632X突变与有丝分裂受损,细胞周期异常,放射状神经母细胞迁移和细胞凋亡相关。异氟醚麻醉下轻度睡眠小鼠模型中,ICK缺陷小鼠强直性阵挛性惊厥,多刺脑电图等小儿肌阵挛性癫痫症状更为频繁(P=0.02)。

研究认为肠细胞激酶杂合突变与小儿肌阵挛性癫痫相关。

原始出处:

Julia N. Bailey et al. Variant Intestinal-Cell Kinase in Juvenile Myoclonic Epilepsy. N Engl J Med. March 15, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1984226, encodeId=e8ea19842264c, content=<a href='/topic/show?id=420681092f7' target=_blank style='color:#2F92EE;'>#肌阵挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81092, encryptionId=420681092f7, topicName=肌阵挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Fri Nov 02 07:18:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342473, encodeId=49dd13424e315, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Mar 17 00:18:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496005, encodeId=826d149600523, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sat Mar 17 00:18:00 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
    2018-11-02 zxl729
  2. [GetPortalCommentsPageByObjectIdResponse(id=1984226, encodeId=e8ea19842264c, content=<a href='/topic/show?id=420681092f7' target=_blank style='color:#2F92EE;'>#肌阵挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81092, encryptionId=420681092f7, topicName=肌阵挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Fri Nov 02 07:18:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342473, encodeId=49dd13424e315, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Mar 17 00:18:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496005, encodeId=826d149600523, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sat Mar 17 00:18:00 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1984226, encodeId=e8ea19842264c, content=<a href='/topic/show?id=420681092f7' target=_blank style='color:#2F92EE;'>#肌阵挛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81092, encryptionId=420681092f7, topicName=肌阵挛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5eee468, createdName=zxl729, createdTime=Fri Nov 02 07:18:00 CST 2018, time=2018-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342473, encodeId=49dd13424e315, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Mar 17 00:18:00 CST 2018, time=2018-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1496005, encodeId=826d149600523, content=<a href='/topic/show?id=9c516685eea' target=_blank style='color:#2F92EE;'>#激酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66857, encryptionId=9c516685eea, topicName=激酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73449239400, createdName=redcrab, createdTime=Sat Mar 17 00:18:00 CST 2018, time=2018-03-17, status=1, ipAttribution=)]
    2018-03-17 redcrab